Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib plus lenalidomide and dexamethasone versus placebo plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
NL-OMON55577Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib + lenalidomide + dexamethasone with Placebo + lenalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Sep 2013; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON55577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55577.